新的治疗组合让17个CLL病人每天停止服药长达2年, A new treatment combo let 17 CLL patients stop daily meds for up to 2 years while staying in remission.

第一阶段试验表明,将实验性抗体亚麻黄碱与ibratutinib结合起来,使17名慢性淋巴细胞白血病病人在保持呼吸平衡的同时,可以停止每天治疗12至24个月。 A phase I trial shows that combining the experimental antibody ianalumab with ibrutinib allowed 17 chronic lymphocytic leukemia patients to stop daily treatment for 12 to 24 months while maintaining remission. 在39名对ibrutinib没有很好反应的病人中测试的这种综合疗法是安全的,具有可管理的副作用,并导致43.6%的参与者出现无法检测的可计量残余疾病。 The combination, tested in 39 patients who had not responded well to ibrutinib alone, was safe with manageable side effects and led to undetectable measurable residual disease in 43.6% of participants. 近60%的患者接受了治疗,感染率低于预期。 Nearly 60% responded to treatment, and infection rates were lower than expected. 研究人员说,这种方法可能促成有时间限制的治疗,提高生活质量,但需要开展更大的研究,以确认长期有效性。 Researchers say the approach may enable time-limited therapy, improving quality of life, but larger studies are needed to confirm long-term effectiveness.